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Antimicrobial promotion of pig 
growth is associated with tissue-
specific remodeling of bile acid 
signature and signaling
Ignacio R. Ipharraguerre  1,2, Jose J. Pastor  2, Aleix Gavaldà-Navarro3, Francesc Villarroya3 
& Alessandro Mereu2,4
The spread of bacterial resistance to antimicrobials (AMA) have intensified efforts to discontinue the 
non-therapeutic use of AMA in animal production. Finding alternatives to AMA, however, is currently 
encumbered by the obscure mechanism that underlies their growth-promoting action. In this report, we 
demonstrate that combinations of antibiotics and zinc oxide at doses commonly used for stimulating 
growth or preventing post-weaning enteritis in pigs converge in promoting microbial production of 
bile acids (BA) in the intestine. This leads to tissue-specific modifications in the proportion of BA, 
thereby amplifying BA signaling in intestine, liver, and white adipose tissue (WAT). Activation of BA-
regulated pathways ultimately reinforces the intestinal protection against bacterial infection and 
pathological secretion of fluids and electrolytes, attenuates inflammation in colon and WAT, alters 
protein and lipid metabolism in liver, and increases the circulating levels of the hormone FGF19. 
Conceivably, these alterations could spare nutrients for growth and improve the metabolic efficiency 
of AMA-treated animals. This work provides evidence that BA act as signaling molecules that mediate 
host physiological, metabolic, and immune responses to the AMA-induced alterations in gut microbial 
metabolism, eventually permitting the growth-promoting action of AMA. Consequently, BA emerge as 
a promising target for developing efficacious alternatives to AMA.
For more than 50 years, low doses of antibiotics either alone or in combination with pharmacological levels of 
heavy metals (i.e., zinc and copper) have been widely used in swine production to accelerate growth1,2. More 
recently, oral administration of similar levels of these antimicrobial agents (AMA) but for disease prevention 
has become recurrent in pig farming, particularly in countries where antibiotic growth promoters have been 
banned3,4. An expanding body of evidence, however, links such practices to the spread of antibiotic-resistant 
bacteria in animals and humans5,6. It is crucial therefore to find ways for reducing the overuse of AMA in 
food-producing animals without jeopardizing their health and wellbeing as well as the economic viability of farm 
operations. Intriguingly, AMA consistently promote weight gain irrespective of their bacterial spectrum1, but a 
uniting mechanism underlying their growth-enhancing action remains elusive. As expected, this uncertainty 
hinders the development of alternative strategies to AMA7,8.
A number of studies have shown that AMA-induced weight gain is accompanied by alterations in gut micro-
bial ecology, which frequently entails suppression of gram-positive commensals and proliferation of bacterial 
communities with enhanced capacity for dietary energy harvest9–12. These changes include increased lipid absorp-
tion by the host owing to reduced activity of bacterial bile salt hydrolases (BSH) and the associated deconjugation 
of bile salts in the intestine13. In addition, several data sets indicate that the growth-permitting effect of AMA also 
involves reduced inflammation and immune activation (mainly in the intestinal mucosa), although the under-
lying mechanism is currently unclear and evidence from animals other than mice is scant14–19. In addition to 
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these effects, emerging data from murine models suggest that AMA can cause variations in the biosynthesis of 
bile acids (BA) and the instructive functions that they exert in the metabolic and immune interplay between the 
host and its gut microbiota. Such functions are primarily mediated by the nuclear receptor farnesoid X receptor 
(FXR) and the G protein-coupled receptor TGR5 (TRG5), both of which are involved in the regulation of BA, 
energy, and immune homeostasis in the host20,21. In this regard, disruption of mouse microbiota by antibiotics 
not only altered synthesis and enterohepatic cycling of primary (produced by the liver) and secondary (produced 
by bacteria) BA but also affected BA signature and FXR signaling in a tissue-specific manner22,23. Furthermore, 
both increased BSH activity due to expression of cloned BSH in the gut24 and decreased BSH activity due to sup-
pression of intestinal Lactobacilli25 were associated with weight gain in rodents. The explanation for this apparent 
contradiction involves differential patterns of BA signaling in the intestine and liver in response to opposite 
fluctuations in the local concentration of FXR-antagonist primary bile salts and FXR-agonist secondary BA24,25. 
An additional feature of BA is their toxicity to bacteria, which contributes to maintain microbial balance within 
the gut26. Dysregulation of bacterial transformations in the large bowel, in particular 7α-dihydroxylation, was 
recently found to correlate with dysbiosis and concomitant intestinal pathologies27. By interacting with intestinal 
FXR and TGR5, BA were also shown to induce mechanisms that protect the gut epithelium against barrier dys-
function, bacteria invasion, and overstimulation of the immune-inflammatory axis28,29.
Collectively, evidence supports the hypothesis that alterations in BA metabolism, signature, and signaling rep-
resent a conceivable mechanism for the growth-promoting action of the non-therapeutic use of AMA. Certainly, 
this mechanism integrates many of the previously proposed effects of AMA11,13–15,30,31. It is important to note, 
however, that the chemical structure of BA, including conjugation and degree of hydroxylation, determines their 
ability to activate or inhibit signaling pathways and major differences in BA chemistry exist across animal spe-
cies32. Moreover, the regulatory functions of BA in food-producing animals and the influence that customary 
combinations of AMA rather than single interventions have on them remain largely unknown. In this report, 
data from two independent studies are presented. The first study investigated the impact of a combination of 
zinc oxide, amoxicillin, and colistin (ZAC) (Supplementary Table S1) on BA metabolism, profile and regulatory 
actions in the intestine and liver of weaned piglets. Two years later, a second study was conducted to confirm and 
expand findings from the first study. To this end, a combination of zinc oxide, chlortetracycline, and tiamulin 
(ZCT) (Supplementary Table S2) was used to cover a different bacterial spectrum than ZAC and BA instructive 
functions were mainly examined in tissues outside the enterohepatic system. For these reasons, not all biomarkers 
were measured in both studies. We chose ZAC and ZCT because both AMA combinations are extensively used 
in commercial pig production in Europe to prevent weaning-induced enteric disorders and growth check. This 
work identifies BA as integrators and modulators of the host physiological, metabolic, and immune-inflammatory 
responses to the AMA-mediated alterations in gut microbial metabolism, which makes them a promising target 
for the development of efficacious alternatives to AMA.
Results
Antimicrobials promote growth independently of the metabolic phenotype. Following prac-
tices currently used in commercial pig production, two cohorts of piglets from the same commercial operation 
were weaned averaging 23 ± 2 days of age, transported to a research nursing facility, and therein fed for 35 
days cereal-based diets medicated with widely used combinations of AMA in two independent experiments. 
Antimicrobial combinations were ZAC or ZCT at dosing levels routinely used for preventing bacterial enteri-
tis and stimulating pig growth. Control piglets (CON) received no AMA. In both experiments, AMA-fed pigs 
gained more body weight (BW) than their control counterparts. The magnitude of this effect was similar for the 
two AMA combinations, which totaled at the end of the experiment 1.6 (9%) and 1.9 (11%) kg of BW for pigs 
fed ZAC or ZCT, respectively (Fig. 1A and B). Consistent with previous findings1, such responses were not asso-
ciated with differences in feed intake between CON and ZAC (Fig. 1C) or CON and ZCT (Fig. 1D). A possible 
mechanistic component of the growth-permitting action of AMA is enhanced energy absorption, particularly as 
lipids13. As compared with CON, however, ZAC increased the circulating levels of leptin (Fig. 1M) and adiponec-
tin (Fig. 1O), whereas ZCT reduced the plasma concentrations of insulin (Fig. 1L) and glucose (Fig. 1F), and none 
of them affected lipid fractions in circulation (Fig. 1G–J).
Antimicrobials converge in altering bile acid biosynthesis by gut microbiota. To assess the 
impact of AMA on gut microbiota, samples of colonic contents from both cohorts were analyzed by massive 
sequencing of the V1-V2 regions of the 16 S rRNA gene. At the phylum level, all groups presented microbial 
compositions (Fig. 2A and B) representative of the metagenome prevailing in healthy pigs of similar age10. 
Compared with CON, however, ZAC favored the proliferation of Bacteroidetes (65 vs. 74%) mainly at the expense 
of Firmicutes (30 vs. 23%) and Proteobacteria (1.9 vs. 0.3%) resulting in reduced microbial diversity within 
(Fig. 2C) and between individuals (Supplementary Table S3). The major BA biotransformations that take place 
in the intestine of humans and rodents are carried out by bacteria that possess bile salt hydrolase (BSH) activity 
and/or 7α-dihydroxylating capacity33. Concerning these bacteria, ZAC drastically decreased the proportion of 
Lactobacillus and Clostridium whereas increased the relative abundance of Bacteroides (Fig. 2E). In contrast, 
the colonic microbiota of ZCT-fed pigs (Fig. 2B and D and Supplementary Table S3), including the propor-
tion of BA-biotransforming bacteria (Fig. 2F), did not differ substantially from that of their CON counterparts. 
Furthermore, whereas ZAC depressed the BSH activity of colonic contents, ZCT resulted in the opposite effect 
(Fig. 3A and B).
Despite their differential effects on gut microbial ecology and BSH activity, both AMA combinations robustly 
enhanced secondary to primary BA ratios in colon (Fig. 3C and D), indicating that AMA administration stimu-
lated microbial conversion (7α-dehydroxylation) of hyocholic acid (HCA) into hyodeoxycholic acid (HDCA) and 
of HDCA and chenodeoxycholic acid (CDCA) into lithocholic acid (LCA). Even though the microbial identity 
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remains unclear, these findings demonstrate that combinations of AMA that are traditionally used in pig produc-
tion for growth promotion or disease prevention coincide in altering in a similar way the metabolism of BA by gut 
microbiota irrespective of their bacterial spectrum.
Antimicrobials modify the profile of bile acid in multiple tissues. Given the converging influence 
of AMA combinations on bacterial BA biosynthesis, we then measured BA in multiple compartments of the 
enterohepatic system. The ileal epithelia of CON and medicated pigs were enriched with BA before bile salts 
(Supplementary Fig. S1). The concentrations of total BA in colon and liver, but not in ileum and plasma, were 
reduced by ZCT (Supplementary Fig. S2). The profile of BA, however, was markedly altered by both AMA com-
binations in all examined tissues. Pigs treated with ZAC and ZCT shared a reduction in the proportion of HCA 
in colonic mucosa accompanied by an increase in the percentage of CDCA in ileal epithelium plus a remarkable 
surge in the ratio of LCA both in colonic mucosa and systemic circulation (Fig. 3E–J). In addition to these com-
mon alterations, ZAC produced an increase in hepatic CDCA (Fig. 3G) and ileal LCA (Fig. 3I), whereas ZCT 
caused a decline in ileal HCA (Fig. 3F) along with an increase in hepatic LCA (Fig. 3J). Because LCA and CDCA 
are the most potent endogenous agonists of BA receptors20,34, these results denote that administering AMA to 
pigs at levels shown to stimulate growth coincide in expanding the potency of the BA pool within and beyond the 
enterohepatic system.
Antimicrobials enhance the circulating concentration of FGF19. To elucidate the implications of the 
AMA-induced alterations in intestinal BA signature we next examined the BA-FXR-FGF19 signaling pathway in 
ileum and potential target tissues of this enterokine. We observed that Fxr, Fgf19, and porcine genes encoding 
FGF19 receptors (Fgfr4, Fgfr1IIIc, and Klb) were expressed in ileal mucosa (Fig. 4A,B and E). Consistent with 
data from rodents35–37, we also found detectable levels of FGF19 receptors, including Klb, in liver (Supplementary 
Fig. S3), WAT (Fig. 4F and Supplementary Fig. S3) and muscle (Fig. 4G). Not significant differences between 
Figure 1. Growth promotion by in-feed antimicrobials (AMA) is paralleled by inconsistent alterations in the 
metabolic profile of pigs. Two independent cohorts of piglets were weaned and fed for 35 days cereal-based diets 
medicated with combinations of AMA, which were either zinc oxide, amoxicillin, and colistin (ZAC) or zinc 
oxide, chlortetracycline, and tiamulin (ZCT) at dosing levels routinely used for preventing bacterial enteritis 
and stimulating pig growth. Control pigs (CON) received no AMA. Plasma collected on days 34 and 35 were 
used to measure biomarkers by ELISA. Data from the two experiments were combined in the figure. (A,B) 
Weight gain, (C,D) average daily feed intake, and circulating concentration of metabolites (E–J) and hormones 
(K–P) in pigs fed CON or medicated (ZAC and ZCT) diets. Data were analyzed with ANOVA. Least squares 
means ± SEM are plotted, *P < 0.05, **P < 0.01, n = 6–12.
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CON and AMA groups were detected in the mRNA level of ileal Fgf19 (Fig. 4A) and its receptors across exam-
ined tissues (Fig. 4B and E–G). Compared to CON, however, ZAC-fed pigs had higher expression of FGF19 
protein in ileum (Fig. 4C) and animals from both AMA groups experienced a substantial increase (≥ 1-fold) 
in the circulating concentration of FGF19 (Fig. 4D and H). These results indicate that in pigs AMA coincide in 
enhancing BA signaling through the intestinal FXR-FGF19 pathway. They also reveal that, like in rodents35–37, key 
tissues involved in the metabolic regulation of growth possess the signaling machinary required for responding 
to FGF19.
These findings suggest that in pigs CDCA is a more potent FXR agonist than HCA. To explore this possibility, 
we treated ileal explants from CON pigs with these BA and found that, at the same concentration, CDCA resulted 
in a 2-fold higher expression of Fgf19 than HCA (Fig. 4I). Furthermore, the addition of incremental concentra-
tions of HCA into the culture media failed to augment the CDCA-induced expression of Fgf19, which actually 
followed a diminishing trend (Fig. 4J). Taken together, data indicate that the capacity of CDCA to signal through 
the FXR-FGF19 axis is higher than that of HCA.
Figure 2. In-feed antimicrobials (AMA) have irregular influence on the intestinal microbiota of pigs. Two 
independent cohorts of piglets were weaned and fed for 35 days cereal-based diets medicated with combinations 
of AMA, which were either zinc oxide, amoxicillin, and colistin (ZAC) or zinc oxide, chlortetracycline, and 
tiamulin (ZCT) at dosing levels routinely used for preventing bacterial enteritis and stimulating pig growth. 
Control pigs (CON) received no AMA. Colonic contents obtained on days 34 and 35 were used to assess the 
microbiome profile by massive sequencing of the hypervariable regions V1-V2 of the 16 S rRNA gene. Data 
from the two experiments were combined in the figure. (A,B) Composition (percent reads at the phylum level) 
and (C,D) alpha diversity of colonic microbiota from pigs fed CON or medicated (ZAC and ZCT) diets. (E,F) 
Proportion of bile-acid metabolizing bacteria (percent reads at the genus level) in colonic contents of pigs fed 
ZAC (E) or ZCT (F). Data were analyzed with Student t test (percent reads) and non-parametric Montecarlo 
permutation test (alpha diversity). Means ± SEM are plotted, *P < 0.05, **P < 0.01, n = 10–12.
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Intestinal protection by antimicrobials is associated with activation of FXR and TGR5 in the 
intestine. At doses tested herein, AMA have proven ability to prevent intestinal dysfunction and inflamma-
tion in mice14,15 and farm animals2,31,38,39. Coincidentally, the BA sensors FXR and TGR5 participate in the regu-
lation of numerous mechanisms implicated in the defense of the intestine28,29,40, suggesting that altered BA profile 
and signaling may be mechanistic components of the AMA enteroprotective action. We found that, compared 
with CON, the colon of ZAC-treated pigs had modified expression of immune genes regulated by BA sensors28,40, 
including reduced mRNA levels of the inflammatory genes Il8 and Ptgs2 (Fig. 5A) and increased transcripts of 
Ang1 (Supplementary Fig. S4), which encodes a protein (agiogenin 1) with antibacterial and antimycotic effects28. 
These changes were accompanied by augmented BA signaling in colonic mucosa of ZAC animals, as denoted by 
the upregulated expression of genes whose transcription is controlled by FXR (Fig. 5B) or TGR5 (Supplementary 
Fig. S4). Administration of ZCT also repressed the expression of proinflammatory genes in colon (Fig. 5C) but 
did not affect other genes responsive to BA (Fig. 5D and Supplementary Fig. S4).
Early weaning, as carried out in our experiments, disrupts intestinal barrier function in pigs41 and activa-
tion of FXR42 or TGR529 by exogenous ligands prevents the development of this pathology in murine models of 
intestinal inflammation. In assays with Ussing chambers, we observed that the ileal mucosa of ZCT-treated pigs 
had increased transepithelial electrical resistance (Fig. 5E), indicating improved function of the intestinal barrier 
compared with CON animals. Furthermore, ZCT reduced ileal ion transport (Fig. 5F) which is affected in the 
opposite direction by weaning41 as result of excessive secretory activity of the intestine (diarrhea). Collectively, 
these findings confirm the enteroprotective function of AMA in pigs and support the proposition that their mode 
of action involves reinforced BA signaling via intestinal BA sensors.
Antimicrobials remodel bile acid signaling in liver and adipose tissue but not in muscle. After 
confirming that AMA combinations affected BA metabolism and signaling in the intestine, we then focused on 
tissues serving key roles in the metabolic regulation of growth. Compared with CON, administration of ZAC to 
pigs promoted activation of hepatic FXR as indicated by the counterregulatory expression (Fig. 6A) of Shp, a tran-
scriptional corepressor induced by FXR, and Srebp1-c, a transcriptional activator of hepatic lipogenesis repressed 
by FXR via SHP20. In line with these findings, ZAC-treated pigs had lower concentration of triglycerides (TAG) in 
the liver than their CON counterparts (Fig. 6D). They also presented a higher content of hepatic protein (Fig. 6E), 
Figure 3. Feeding antimicrobials (AMA) to pigs alter the synthesis of secondary bile acids and the profile of 
bile acids (BA) in a tissue-specific manner. Two independent cohorts of piglets were weaned and fed for 35 days 
cereal-based diets medicated with combinations of AMA, which were either zinc oxide, amoxicillin, and colistin 
(ZAC) or zinc oxide, chlortetracycline, and tiamulin (ZCT) at dosing levels routinely used for preventing 
bacterial enteritis and stimulating pig growth. Control pigs (CON) received no AMA. The concentration of 
BA was measured via UPLC-MS in samples taken on days 34 and 35. Data from the two experiments were 
combined in the figure. (A,B) Bile salt hydrolase activity (assessed by treating colonic digesta with labeled tauro-
cholic-d5 acid and measuring the formation of cholic acid-d5 via UPLC-MS) and (C,D) primary to secondary 
BA ratios in colonic contents of pigs fed CON or medicated (ZAC and ZCT) diets. (E–J) Relative concentration 
of HCA (E,F), CDCA (G,H), and LCA (I,J) in liver, plasma, and intestinal mucosa of pigs fed ZAC (E,G and 
I) or ZCT (F,H and J). Data were analyzed with ANOVA. Least squares means ± SEM are plotted, *P < 0.05, 
**P < 0.01, n = 10–12, nd = not detected.
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which is in agreement with the regulatory function that FGF19 plays in this organ43. Interestingly, transcript levels 
of enzymes implicated in BA synthesis were not affected by ZAC (Fig. 6B).
In mouse, BA also target adipose tissue, where upon activation of TGR5 induce energy expenditure via 
increased expression of Dio2 in the context of diet-induced obesity20. As compared with CON animals, the sub-
cutaneous WAT (sWAT) of ZCT-treated pigs presented increased expression of Tgr5 (Fig. 6C) but not of Dio2 
and genes involved in thermogenesis and fatty acid oxidation (Supplementary Fig. S5). Instead, administration 
of ZCT reduced the mRNA abundance of Tnfα in sWAT (Fig. 6C), a proinflammatory cytokine downregulated 
by BA through a TGR5-dependent mechanism44. Even though Tgr5 was expressed at detectable levels in skel-
etal muscle, none of the AMA-induced effects on liver and sWAT were observed in this tissue (Supplementary 
Fig. S6).
Discussion
Clarifying the mechanisms by which AMA stimulate weight gain in farm animals is an endeavor of vital impor-
tance that requires disentangling the impact of AMA on the constantly evolving crosstalk between the host and its 
gut microbiota. The complexity entailed by such interactions has encouraged the use of reductionist models based 
on animals (mice), interventions (single medications), and/or conditions (highly-controlled environments and 
diets) that, albeit valuable, are distant from the customary use of AMA in animal production and the features (e.g., 
animal species, husbandry practices, hygiene, etc.) that characterize it11,14–16. Using an experimental approach that 
closely resembles intensive systems of pig production, we show that combinations of AMA with different bacterial 
spectrum at doses commonly used for stimulating growth and preventing post-weaning enteritis converge in 
promoting BW gain and altering the metabolism of BA by gut microbiota as well as the profile and signaling of 
BA in intestinal mucosa, liver, and WAT. In turn, these effects induce growth-supporting adaptations in pathways 
regulated by BA that are implicated in the immunometabolic regulation of BW. Such alterations include improved 
immune tolerance and barrier function of the intestinal mucosa, reduced inflammation in colon and WAT, and, 
most intriguingly, enhanced circulating levels of FGF19. This work provides evidence that BA serve a mechanistic 
role in the growth-permitting action of AMA by acting as signaling molecules that mediate host physiological, 
metabolic, and immune-inflammatory responses to the AMA-induced alterations in gut microbial metabolism.
In recent years, it has become clear that BA are regulatory molecules with endocrine functions that signal 
changes in the immunometabolic interplay between the host and its gut microbiota34. Several studies have shown 
Figure 4. Feeding antimicrobials to pigs enhance the circulating concentration of FGF19 by targeting intestinal 
FXR. Two independent cohorts of piglets were weaned and fed for 35 days cereal-based diets medicated 
with combinations of AMA, which were either zinc oxide, amoxicillin, and colistin (ZAC) or zinc oxide, 
chlortetracycline, and tiamulin (ZCT) at dosing levels routinely used for preventing bacterial enteritis and 
stimulating pig growth. Control pigs (CON) received no AMA. Gene expression was measured by qRT-PCR 
and protein levels by Western blot and ELISA in tissue samples taken on days 34 and 35 or ileal explants. Data 
from the two experiments were combined in the figure. (A,B) Ileal expression of genes encoding components 
of the FGF19 system and (C,D) concentration of FGF19 protein in ileum (C) and plasma (D) of pigs fed CON 
or ZAC. (E–G) Expression of genes encoding components of the FGF19 system in ileum (E), sWAT (F), and 
skeletal muscle (G,H) plasma concentration of FGF19 protein in pigs fed CON or ZCT. In C, FGF19 and β-actin 
specific bands are displayed from cropped blots. Full-length blots are presented in Supplementary Figure S7. 
Data were analyzed with ANOVA. Least squares means ± SEM are plotted, ***P < 0.001, n = 9–12 per group. 
(I,J) Expression of Fgf19 in ileal explants treated with 300 μM of CDCA or HCA (I) or with 3000 μM of CDCA 
in the presence of different amounts of HCA (J). Data were analyzed with Student t test. Means ± SE are plotted, 
*P < 0.05. This assay was performed using explants from 4 independent pigs from the CON group.
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that upsetting the intestinal microbiome of rodents with therapeutic doses of antibiotics causes profound alter-
ations in BA profile, tissue distribution, and expression of genes that are involved in BA, energy, and immune 
homeotasis22,45–47. Interestingly, at sub-therapeutic levels the oral administration of antibiotics to mice resulted in 
less consistent shifts in microbial composition; yet, supported host growth, altered lipid metabolism, and atten-
uated the immune response of the intestinal mucosa11,14,15 through pathways that could possibly be regulated by 
BA20,28,29,40. Mirroring outcomes from murine models, the non-therapeutic addition of antibiotics into the diet 
of pigs had irregular influence on intestinal microbes18 but consistently enhanced BW gain and reduced the cir-
culating concentration of biomarkers of inflammation17 and immune activation18. In addition to antibiotics, the 
feeding of high levels (≥2400 ppm) of zinc oxide to young pigs, a widely used AMA in swine production, stimu-
lated growth with concurrent generation of gut microbial patterns and intestinal immune phenotypes resembling 
the ones generated by antibiotic growth promoters in mice9,12,48. Collectively, available data suggest a causal link 
between the gut microbiota-BA axis and the growth-enhancing action of AMA with diverse bacterial spectrum 
(define herein as low doses of antibiotics and/or high doses of zinc oxide). Nevertheless, the implication of BA in 
mediating physiological, metabolic, and immune responses to AMA has not been established. Furthermore, little 
is known about the regulatory functions of BA in food-producing animals, including pigs.
Figure 5. The enteroprotective action of in-feed antimicrobials in pigs is associated with increased signaling 
through intestinal FXR and TGR5. Two independent cohorts of piglets were weaned and fed for 35 days cereal-
based diets medicated with combinations of AMA, which were either zinc oxide, amoxicillin, and colistin 
(ZAC) or zinc oxide, chlortetracycline, and tiamulin (ZCT) at dosing levels routinely used for preventing 
bacterial enteritis and stimulating pig growth. Control pigs (CON) received no AMA. Gene expression was 
measured by qRT-PCR in intestinal mucosa samples taken on days 34 and 35. Data from the two experiments 
were combined in the figure. (A,C) Expression of proinflammatory genes in colon and (B,D) FXR-target genes 
in ileum of pigs fed CON or medicated (ZAC and ZCT) diets. Data were analyzed with ANOVA. Least squares 
means ± SEM are plotted, *P < 0.05, **P < 0.01, ***P < 0.001, n = 8–12 per group. (E) Transepithelial electrical 
resistance (TER) and (F) ion transport (Isc) in the ileal mucosa of pigs fed CON or ZCT. Data were analyzed 
with ANOVA. Least squares means ± SEM are plotted, *P < 0.05, n = 8. This assay was performed by mounting 
mucosal segments from the mid-ileum in Ussing chambers from CON and ZCT-treated pigs.
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We confirmed in two independent studies that irrespective of their chemical strucuture and  bacterial spec-
trum both AMA interventions consistently increased weight gain by 9 (ZAC) and 11% (ZTC), agreeing with pre-
vious results and the notion that the antimicrobial specificity of AMA do not determine their growth-enhancing 
action1. Evidence from studies with mice11,14,15 and pigs12,18,49,50 clearly indicates that the mode of action of AMA 
involves changes in the gut microbiome. Such alterations could entail selection of bacterial species and genes with 
superior capacity for producing volatile fatty acids and thereby enhance the extraction of dietary energy by the 
host11,50. Additionally, this effect may be amplified by the suppression of bacteria bearing BSH activity, in par-
ticular Lactobacillus species, which is predicted to augment the concentration of bile salts in the intestinal lumen 
and, as a consequence, the emulsification and absorption of lipids13. However, a consistent taxonomical pattern 
or microbial enterotype is certainly not recurrent across published data, raising questions about the universality 
of this mechanism. In line with this observation, we found that ZAC and ZCT had inconsistent effects on the 
diversity and taxonomy of colonic microbes (ZAC influenced them whereas ZCT did not), the abundance of 
BSH-containing bacteria (ZAC repressed them but ZCT had no effects), and the activity of BSH in intestinal con-
tents (ZAC decreased it whereas ZCT did the opposite). In part, these findings agree with previously established 
(positive) associations between antibiotic-induced BW gain and proliferation of Lactobacillus49 and between BW 
Figure 6. Feeding antimicrobials to pigs alter bile acid signaling in liver and subcutaneous white adipose 
(sWAT). Two independent cohorts of piglets were weaned and fed for 35 days cereal-based diets medicated 
with combinations of AMA, which were either zinc oxide, amoxicillin, and colistin (ZAC) or zinc oxide, 
chlortetracycline, and tiamulin (ZCT) at dosing levels routinely used for preventing bacterial enteritis and 
stimulating pig growth. Control pigs (CON) received no AMA. Samples taken on days 34 and 35 were used to 
measure gene expression in liver and sWAT by qRT-PCR and metabolites in liver by ELISA. Data from the two 
experiments were combined in the figure. (A,B) Hepatic expression of genes involved in the regulation of bile 
acid and lipid homeostasis and (D–F) concentration of triglycerides (D), protein (E), and glycogen (F) in liver 
of pigs fed CON or ZAC. (C) Expression of TGR5 and proinflammatory genes in sWAT of pigs fed CON or 
ZCT. Data were analyzed with ANOVA. Least squares means ± SEM are plotted, *P < 0.05, **P < 0.01, n = 9–12 
per group.
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loss and both enhanced24 and reduced25 BSH activity in the gut. Furthermore, ZCT reduced circulating glucose 
and insulin while ZAC increased plasma levels of adiponectin and leptin. These responses are in conflict with the 
metabolic profile associated with high-energy-yielding microbiota11 and suggest that AMA actually improved 
energy utilization (insulin sensitivity)51 rather than energy supply. It is therefore apparent that an energy-yielding 
rearrangement of the structure or metabolism of gut microbiota is not uniformly related to the growth-permitting 
action of AMA.
Based on the expanding body of evidence that links diet-induced modifications of BA metabolism by intes-
tinal microbes to metabolic and health disorders in humans and rodents34,52, we next investigated the impact of 
AMA on the microbial biosynthesis of BA and showed that ZAC and ZCT coincided in increasing the formation 
of HDCA and LCA in colon. This finding reveals that both AMA combinations enhanced bacterial removal 
of the 7α-hydroxy group in HCA and CDCA (7α-dehydroxylation), which quantitatively is the predominant 
microbial BA transformation in the gut53. We also demonstrated that ZAC and ZCT had a congruent impact on 
the BA signature in immunometabolically relevant tissues, mainly characterized by a widespread enrichment 
in LCA. Expectably, the most affected tissue was the intestine, where in addition to LCA, the ileal proportion of 
CDCA was increased by both AMA interventions. CDCA and HCA are the most abundant BA produced by the 
porcine liver though a multistep reaction whose biosynthetic output is determined by the expression of genes 
encoding the enzymes CYP7A1 and CYP4A2154. Because the hepatic expression of these genes was not altered 
by ZAC and only HCA was decreased in colonic mucosa of AMA-treated pigs, it seems that the preferential use 
of this tri-hydroxylated BA (HCA) for the production of secondary BA by gut microbiota (rather than alterations 
in hepatic synthesis) dictated the observed changes in BA profiles. Noteworthy, this mechanism greatly differs 
from the previously described for antibiotics administered orally at therapeutic levels to rodents, which comprises 
suppression of BA transformations by intestinal microbes, in particular deconjugation and 7α-dehydroxylation, 
along with alterations in BA production by hepatocytes22,45–47.
Consistent with the notion that in rodents LCA and CDCA are the most potent endogenous agonists of the BA 
receptors TGR5 and FXR, respectively20,34, we next discovered that the AMA-induced alterations in BA profiles 
were associated with tissue-specific activation of pathways regulated by BA. In the intestines, FXR and TGR5 
control signaling routes implicated in mucosal protection against inflammation, bacterial invasion, and dysreg-
ulated secretion of fluids and electrolytes44,55,56. It is important to note that early weaning, as performed in our 
experiments, has long-lived detrimental effects on such intestinal functions41. Concomitantly, both AMA combi-
nations dampened the colonic expression of pro-inflammatory, NF-κB-dependent genes (Ptgs2, Il8) known the 
be controlled by FXR and TGR540,56. Additionally, in colon ZAC induced genes regulated by FXR (Ang1, Tgr5) 
and TGR5 (Gcg, Pcsk1) that encode peptides responsible for preventing microbial infection (agiogenin)28,42 and 
maintaining the structural and functional integrity of the intestinal epithelium (GLP-2)57,58. Furthermore, ZCT 
attenuated permeability and secretory activity of ileal mucosa, pointing towards FXR-mediated inhibition of 
pathological paracellular transport42 and activity of Na+/K+ adenosine triphosphatase pumps as well as cystic 
fibrosis transmembrane conductance regulator channels55. Our findings not only agree with previously described 
enteroprotective effects of AMA14–19 and BA59,60 but also uncovered that they exert BA-mediated instructive func-
tions in WAT and liver. The reciprocal changes in the expression of Tgr5 and Tnfα in sWAT of ZCT-treated pigs 
along with the increased circulating levels of LCA and the immunosuppressive function of TGR5 in immune 
cells44,56, suggest that AMA triggered an anti-inflammatory process in WAT comprising down-regulation of the 
NF-κB-inflammatory pathway via LCA-mediated activation of TGR5 in WAT-resident macrophages. In addi-
tion to exert widespread immunomodulatory effects, we found that the alteration of BA signature by AMA also 
affected liver metabolism. In agreement with previous findings in mice61, the ability of ZAC to enhancing BA 
signaling through hepatic FXR resulted in counterregulatory effects on the expression of Shp and Srebp1-c and 
the consequential reduction in liver TAG. Certainly, this mechanism might have accounted for the reported 
repression of lipogenic genes in the liver of mice that were fed low-doses of antibiotics from weaning onwards15. 
Collectively, our results provide a mechanistic explanation for the increasingly recognized capacity of AMA of 
heightening the defense of intestinal mucosa and expand published data by showing that, irrespective of their 
bacterial spectrum, AMA target in a similar fashion the immune and metabolic homeostasis of tissues (WAT, 
liver) serving critical roles in the regulation of animal growth.
Further supporting the prediction that the non-therapeutic use of AMA entails alterations in BA signature 
and signaling, we demonstrated that both AMA interventions consistently increased the circulating concentra-
tion of FGF19. This emerging hormone is produced by the ileum in response to the BA-dependent activation 
of intestinal FXR62. Previous work showed that the enteral administration of CDCA to pigs enhances plasma 
FGF1959 and herein we proved that CDCA induces Fgf19 expression in the porcine ileum more potently than 
HCA. Therefore, the opposing changes in the intestinal proportion of CDCA (increased) and HCA (decreased) 
caused by AMA likely colluded to promote the synthesis and release of FGF19 into circulation of medicated 
animals. Most biological functions of FGF19 are mediated by the interaction between FGFR4 and β-Klotho62,63. 
Expanding previous results from our group64, we showed that genes encoding these receptors are expressed at 
detectable levels in intestine, liver, WAT and muscle of pigs and that the abundance of their mRNA transcripts 
is not affected by AMA. Strikingly, our findings suggest that AMA intensify endocrine FGF19 signaling in tis-
sues implicated in the regulation of growth. The main target of this enterokine is the liver, where FGF19 inhibits 
production of BA, glucose and fatty acids while stimulates synthesis of glycogen and protein63,65. Even though 
consistent alterations in the hepatic levels of BA and glycogen were not observed, the AMA-mediated changes in 
hepatic TAG (decreased) and protein (increased) suggest that amplified activity of the FGF19-FGFR4/β-Klotho 
pathway cooperated with the BA-FXR cascade to altering liver metabolism. In obese rodents, pharmacologic 
levels of FGF19 activate FGFR1/β-Klotho expressed in brain, liver, and WAT to cause weight loss and insulin sen-
sitivity through increased energy expenditure63,66. We showed that the expression of genes involved in fatty acid 
oxidation and thermogenesis in sWAT were not affected by ZCT, which along the congruent gain in BW triggered 
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by both medicinal treatments indicate that AMA does not promote FGF19 secretion to the extent required for 
activating such a mechanism. More important, recent evidence reveals that FGF19 promotes accretion of skeletal 
muscle mass through β-Klotho-dependent activation of the extracellular-signal-regulated protein kinase 1/2 and 
the ribosomal protein S6 kinase37. Because FGF19 acts upon the same signaling machinary to regulate protein 
synthesis in liver63, it seems reasonable to speculate that FGF19 is indeed a novel endocrine component of the 
growth-promoting action of AMA.
In summary, we demonstrate that combinations of AMA with different bacterial spectrum at doses commonly 
used for stimulating growth or preventing post-weaning enteritis in pigs promote the production of secondary 
BA by colonic microbiota (Fig. 7). In turn, this leads to tissue-specific increases in the proportion of BA that are 
most potent agonists of FXR and TGR5. As a consequence, BA signaling is amplified in intestine, liver, and WAT, 
which ultimately reinforces the protection of the intestinal mucosa against bacterial infection and pathological 
secretion of fluids and electrolytes, attenuates inflammation in colon and WAT, decreases hepatic lipogenesis, 
increases protein synthesis in liver, and stimulates the release of FGF19 into circulation. These alterations likely 
spare nutrients for growth by minimizing the nutritional cost associated with acute or chronic stimulation of 
the immune-inflammatory response resulting from challenging episodes during the lifetime of food-producing 
animals67,68. Additionally, we predict that FGF19 functions as an endocrine factor that improves the metabolic 
efficiency of AMA-treated animals by regulating energy and protein metabolism in liver and skeletal muscle. 
Certainly, more research is needed to confirm this hypothesis. This work identifies BA as integrators and modula-
tors of the host physiological, metabolic, and immune-inflammatory responses to the AMA-mediated alterations 
in gut microbial metabolism, which makes them a promising target for the development of efficacious alternatives 
to AMA.
Methods
Details are in Supplementary Methods
Animal Experiments. All experimental procedures were approved by the Laboratory Animal Care Advisory 
Committee of the Faculty of Veterinary Sciences of the Universitat Autónoma de Barcelona, Spain and in accord-
ance with the Guidelines for Animal Experimentation set by the same institution. A total of 120 Largewhite 
Figure 7. Model for bile acid (BA)-induced adaptations underlying growth promotion by antimicrobials 
(AMA) in pigs. The feeding of AMA to pigs promote the production of secondary BA by intestinal microbiota, 
resulting in tissue-specific increases in the proportion of BA that are most potent agonists of FXR and TGR5 
(i.e., CDCA and LCA). As a result, BA signaling is amplified in ileum, colon, liver and WAT. Such activations 
lead to alterations in host intestinal physiology (i.e., reduced permeability and secretory activity), immunity 
(enhanced intestinal production of antimicrobial peptides, diminished inflammation in colon and WAT), 
and metabolism (decreased hepatic lipogenesis, heightened protein synthesis in liver and possibly in skeletal 
muscle). As a consequence, the immunometabolic demand for nutrients may be minimized thereby sparing 
nutrients for supporting animal growth. In addition, FGF19 may act as a hormone mediating the upregulation 
of protein synthesis in liver and skeletal muscle. Arrow head = induction, flat head = inhibition, CFTR = cystic 
fibrosis transmembrane receptor.
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x Landrace x Pietrain, newly-weaned (22–23 days of age) pigs (60 of each sex) were obtained from the same 
commercial operation and used in two 35-day experiments conducted independently two years apart. In exper-
iment 1, 72 piglets were distrusted into 12 pens (6 pigs/pen) and offered ad libitum access to water and feeds that 
were fed either untreated (CON; n = 6) or medicated with zinc oxide, colistin, and amoxicillin (ZAC) at doses 
indicated in Supplementary Table S1. In experiment 2, 48 piglets were assigned to individual pens and offered ad 
libitum access to water and diets, which were fed either untreated (CON; n = 24) or supplemented with zinc oxide, 
chlortetracycline, and tiamulin (ZCT) at doses shown in Supplementary Table S2. Starting at weaning, BW and 
feed intake were measured weekly in both experiments.
Sample Collection. On day 34 and 35 of both experiments, 12 animals per group were selected and killed to 
collect samples of blood, intestinal contents, and tissues using procedures described in Supplementary Methods.
Explant Assay. On day 34 of experiment 2, a portion of 10 cm from the mid-ileum of CON piglets was 
flushed with PBS 1 × , cut into 2–3 mm transversal slices and incubated in Dulbecco’s modified eagle medium 
containing the indicated concentrations of CDCA and/or HCA for 4 hours.
Ussing Chamber Assay. On day 34 and 35 of experiment 2, ileal mucosa from the mid-ileum of CON and 
ZCT pigs were mounted in modified Ussing chambers to measure transepithelial electrical resistance (TER) and 
ion transport (Isc). Parameters were recorded every 10 seconds for a total of 2 h.
Gut Microbiota Analysis. Samples of colonic content were processed to isolate bacterial DNA to assess the 
microbiome profile by massive sequencing of the hypervariable regions V1-V2 of the 16 S rRNA gene.
Bile Acid Analysis. Bile acids were measured using UPLC-MS following procedures described by Li et al.25 
with modifications detailed in Supplementary Methods.
Bile Salt Hydrolase Assay. Enzyme activity was measured based on the generation of cholic acid-d5 
after incubation of tauro-cholic acid-d5 (25 mM, Toronto Research Chemicals, Toronto, Canada) with proteins 
extracted from colonic contents (100 µg/mL) in 3 mM sodium acetate buffer (pH = 5.2). After 20 min incuba-
tion at 37 °C, the reaction was stopped with of IS solution (CDCA-d4) in acetonitrile and fast frozen in dry ice. 
Samples were analyzed using UPLC-MS as described for BA.
Gene-Expression Analysis. Total RNA from homogenized tissues was isolated using a column 
affinity-based method (NucleoSpin RNA II; Macherey-Nagel, Düren, Germany). and transcribed into cDNA 
using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems/Life Technologies, Foster City, CA, 
USA). Quantitative real-time PCR was carried out using the specific porcine TaqMan Gene Expression Assays 
(Applied Biosystems, USA) or the primers pairs (Sigma-Aldrich, St. Louis, MO, USA) with SYBR Select Master 
Mix (Applied Biosystems, USA) specified in Supplementary Table S4.
Hormone and Metabolite Quantification. FGF19 protein levels in plasma (100 µL) were assayed using 
a Pig Fibroblast Growth Factor 19 (FGF19) ELISA Kit (CSB-E17583p; Cusabio, China). FGF19 protein levels in 
liver and ileum were inmunodetected by western blot using primary 1/500 anti-FGF19 (ab85042, Abcam Plc, 
Cambridge, UK) antibody and 1/5000 anti-β-actin (A5441, Sigma-Aldrich) antibody for loading normalization. 
Commercially available kits and reagents were used to assess plasma insulin (AKRIN-013T; Shibayagi Co., Ltd., 
Shibukawa, Japan), adiponectin (RD591023200R; BioVendor R&D, Brno, Czech Republic), leptin (026475; US 
Biological, Swampscott, MA, USA), glucose (G3293; Sigma-Aldrich), non-esterified fatty acids (NEFA) (434–
91795, 436–91995; Wako Chemicals GmbH, Neuss, Germany), and triglycerides (TR0100; Sigma-Aldrich). 
Glycogen, triglycerides and protein content in liver, were measured in homogenized tissue using the Glycogen 
Assay Kit (MAK016; Sigma-Aldrich), the Serum Triglyceride Determination Kit (TR0100; Sigma-Aldrich) or the 
BCA assay, respectively.
Statistical Analysis. Animal performance parameters including feed consumption and body weight gain 
were analyzed using a mixed-effect model with repeated measures in time (week). In the model, pen (experiment 
1) or pig (experiment 2) nested within treatment were entered as random variables and treatment, time and their 
two-way interaction were considered as fixed effects. The same mixed-model with pig as the experimental unit 
but without repeated measures was used to analyze concentration of bile acids, hormones, and metabolites as 
well as bile salt hydrolase activity, transepithelial electrical resistance, and short circuit current. Gene expression 
data were analyzed using Student t test. Statistical analyses were performed with SAS (release 9.2, SAS Institute). 
Microbial raw sequencing reads were demultiplexed, quality-filtered and analyzed using QIIME 1.9.169.
Data Availability Statement
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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